These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36982940)

  • 1. Estrogen Receptor β4 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer.
    Bano A; Stevens JH; Modi PS; Gustafsson JÅ; Strom AM
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen Receptor Beta 1: A Potential Therapeutic Target for Female Triple Negative Breast Cancer.
    Dey P; Wang A; Ziegler Y; Kumar S; Yan S; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
    Endocrinology; 2022 Oct; 163(12):. PubMed ID: 36251879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness.
    Lan J; Wei G; Liu J; Yang F; Sun R; Lu H
    Theranostics; 2022; 12(6):2598-2612. PubMed ID: 35401817
    [No Abstract]   [Full Text] [Related]  

  • 4. Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival.
    Takano EA; Younes MM; Meehan K; Spalding L; Yan M; Allan P; Fox SB; Redfern A; Clouston D; Giles GG; Christie EL; Anderson RL; Zethoven M; Phillips KA; Gorringe K; Britt KL
    BMC Cancer; 2023 May; 23(1):459. PubMed ID: 37208678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer.
    Yan S; Dey P; Ziegler Y; Jiao X; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
    Breast Cancer Res Treat; 2021 Jan; 185(2):281-292. PubMed ID: 33001337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
    Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
    Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer.
    Wang J; Zhang C; Chen K; Tang H; Tang J; Song C; Xie X
    Breast Cancer Res Treat; 2015 Jul; 152(2):255-69. PubMed ID: 26070269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FBXL2 promotes E47 protein instability to inhibit breast cancer stemness and paclitaxel resistance.
    Li F; Niu M; Qin K; Guo R; Yi Y; Xu J; Li L; Xie S; Fu M; Wen N; Liao W; Xiao ZJ
    Oncogene; 2023 Jan; 42(5):339-350. PubMed ID: 36460773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERβ1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1.
    Song W; Tang L; Xu Y; Sun Q; Yang F; Guan X
    J Exp Clin Cancer Res; 2017 Jun; 36(1):75. PubMed ID: 28583190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function.
    Bado I; Nikolos F; Rajapaksa G; Gustafsson JÅ; Thomas C
    Oncotarget; 2016 Mar; 7(12):13599-611. PubMed ID: 26871946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells.
    Mukherjee P; Gupta A; Chattopadhyay D; Chatterji U
    Sci Rep; 2017 Aug; 7(1):9170. PubMed ID: 28835684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LINC00115 promotes chemoresistant breast cancer stem-like cell stemness and metastasis through SETDB1/PLK3/HIF1α signaling.
    Luo F; Zhang M; Sun B; Xu C; Yang Y; Zhang Y; Li S; Chen G; Chen C; Li Y; Feng H
    Mol Cancer; 2024 Mar; 23(1):60. PubMed ID: 38520019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
    Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
    J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.
    Samanta D; Gilkes DM; Chaturvedi P; Xiang L; Semenza GL
    Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5429-38. PubMed ID: 25453096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment.
    Lu H; Tran L; Park Y; Chen I; Lan J; Xie Y; Semenza GL
    Cancer Res; 2018 Aug; 78(15):4191-4202. PubMed ID: 29880481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer.
    Reese JM; Suman VJ; Subramaniam M; Wu X; Negron V; Gingery A; Pitel KS; Shah SS; Cunliffe HE; McCullough AE; Pockaj BA; Couch FJ; Olson JE; Reynolds C; Lingle WL; Spelsberg TC; Goetz MP; Ingle JN; Hawse JR
    BMC Cancer; 2014 Oct; 14():749. PubMed ID: 25288324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ERβ4 variant induces transformation of the normal breast mammary epithelial cell line MCF-10A; the ERβ variants ERβ2 and ERβ5 increase aggressiveness of TNBC by regulation of hypoxic signaling.
    Faria M; Karami S; Granados-Principal S; Dey P; Verma A; Choi DS; Elemento O; Bawa-Khalfe T; Chang JC; Strom AM; Gustafsson JÅ
    Oncotarget; 2018 Feb; 9(15):12201-12211. PubMed ID: 29552303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells.
    Liu P; Kumar IS; Brown S; Kannappan V; Tawari PE; Tang JZ; Jiang W; Armesilla AL; Darling JL; Wang W
    Br J Cancer; 2013 Oct; 109(7):1876-85. PubMed ID: 24008666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.